益生菌改善糖尿病患者肠道屏障的作用机制研究进展

摘要
图/表
参考文献(0)
相关文章 (15)

全文: PDF (1311 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要糖尿病在全球的发病率不断升高，近来研究表明肠道菌群与糖尿病的发生及发展进程具有一定的关联。而益生菌作为能够调节肠道菌群组成的活性微生物在发挥抗糖尿病作用的同时，也能够改善糖尿病患者原本受损的肠道屏障功能。本篇综述围绕肠道屏障在益生菌改善糖尿病患者肠道代谢中的作用及其机制研究进行论述，旨在为临床治疗及预后评估提供新的方向和策略。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	费菲
	陈燕燕
	杨梦婷
	李丽
	陈茜
	李张左
	侯寒进
	龚爱华

关键词 ：糖尿病, 益生菌, 肠道屏障, 肠道菌群, 代谢产物, 降糖机制

收稿日期: 2023-02-08

基金资助:国家自然科学基金资助项目（81772694）

通讯作者: 龚爱华（通讯作者），教授，博士生导师，E-mail： ahg5@163.com

作者简介: 费菲（1998—），女，硕士研究生；

引用本文:

费菲，陈燕燕，杨梦婷，李丽，陈茜，李张左，侯寒进，龚爱华. 益生菌改善糖尿病患者肠道屏障的作用机制研究进展[J]. 江苏大学学报:医学版, 2023, 33(04): 359-363，368.

链接本文:

http://zzs.ujs.edu.cn/xbyxb/CN/ 或 http://zzs.ujs.edu.cn/xbyxb/CN/Y2023/V33/I04/359

［1］Qiao J, Zhang Z, Ji S, et al. A distinct role of STING in regulating glucose homeostasis through insulin sensitivity and insulin secretion［J］. Proc Natl Acad Sci U S A, 2022, 119(7): e2101848119.
［2］Dujic T, Causevic A, Bego T, et al. Organic cation transporter 1 variants and gastrointestinal side effects of metformin in patients with type 2 diabetes［J］. Diabet Med, 2016, 33(4): 511-514.
［3］Lalau JD, Kajbaf F, Protti A, et al. Metforminassociated lactic acidosis (MALA): Moving towards a new paradigm［J］. Diabetes Obes Metab, 2017, 19(11): 1502-1512.
［4］李林斌, 吴冕, 杨云稀, 等. 2型糖尿病患者中性粒细胞趋化功能受损及可能机制［J］. 江苏大学学报(医学版), 2022, 32(2): 146-151.
［5］Goodwin G. Type 1 diabetes mellitus and celiac disease: distinct autoimmune disorders that share common pathogenic mechanisms［J］. Horm Res Paediatr, 2019, 92(5): 285-292.
［6］Kemppainen KM, Ardissone AN, DavisRichardson AG, et al. Early childhood gut microbiomes show strong geographic differences among subjects at high risk for type 1 diabetes［J］. Diabetes Care, 2015, 38(2): 329-332.
［7］Zhou H, Sun L, Zhang S, et al. Evaluating the causal role of gut microbiota in type 1 diabetes and its possible pathogenic mechanisms［J］. Front Endocrinol (Lausanne), 2020, 11: 125.
［8］Watts T, Berti I, Sapone A, et al. Role of the intestinal tight junction modulator zonulin in the pathogenesis of type I diabetes in BB diabeticprone rats［J］. Proc Natl Acad Sci U S A, 2005, 102(8): 2916-2921.
［9］Zhao L, Lou H, Peng Y, et al. Elevated levels of circulating shortchain fatty acids and bile acids in type 2 diabetes are linked to gut barrier disruption and disordered gut microbiota［J］. Diabetes Res Clin Pract, 2020, 169: 108418.
［10］Sorini C, Cosorich I, Lo Conte M, et al. Loss of gut barrier integrity triggers activation of isletreactive T cells and autoimmune diabetes［J］. Proc Natl Acad Sci U S A, 2019, 116(30): 15140-15149.
［11］Mnsted M, Falck ND, Pedersen K, et al. Intestinal permeability in type 1 diabetes: an updated comprehensive overview［J］. J Autoimmun, 2021, 122: 102674.
［12］Yang H, Liu Y, Cai R, et al. A narrative review of relationship between gut microbiota and neuropsychiatric disorders: mechanisms and clinical application of probiotics and prebiotics［J］. Ann Palliat Med, 2021, 10(2): 2304-2313.
［13］Archer AC, Muthukumar SP, Halami PM. Lactobacillus fermentum MCC2759 and MCC2760 alleviate inflammation and intestinal function in highfat dietfed and streptozotocininduced diabetic rats［J］. Probiotics Antimicrob Proteins, 2021, 13(4): 1068-1080.
［14］Wu T, Zhang Y, Li W, et al. Lactobacillus rhamnosus LRa05 ameliorate hyperglycemia through a regulating glucagonmediated signaling pathway and gut microbiota in type 2 diabetic mice［J］. J Agric Food Chem, 2021, 69(31): 8797-8806.
［15］Hao J, Zhang Y, Wu T, et al. The antidiabetic effects of Bifidobacterium longum subsp. longum BL21 through regulating gut microbiota structure in type 2 diabetic mice［J］. Food Funct, 2022, 13(19): 9947-9958.
［16］Rustanti N, Murdiati A, Juffrie M, et al. Effect of probiotic Lactobacillus plantarum Dad13 on metabolic profiles and gut microbiota in type 2 diabetic women: a randomized doubleblind controlled trial［J］. Microorganisms, 2022, 10(9): 1806.
［17］Toejing P, Khampithum N, Sirilun S, et al. Influence of Lactobacillus paracasei HII01 supplementation on glycemia and inflammatory biomarkers in type 2 diabetes: a randomized clinical trial［J］. Foods, 2021, 10(7): 1455.
［18］Mobini R, Tremaroli V, Sthlman M, et al. Metabolic effects of Lactobacillus reuteri DSM 17938 in people with type 2 diabetes: a randomized controlled trial［J］. Diabetes Obes Metab, 2017, 19(4): 579-589.
［19］Brunkwall L, OrhoMelander M. The gut microbiome as a target for prevention and treatment of hyperglycaemia in type 2 diabetes: from current human evidence to future possibilities［J］. Diabetologia, 2017, 60(6): 943-951.
［20］NavabMoghadam F, Sedighi M, Khamseh ME, et al. The association of type Ⅱ diabetes with gut microbiota composition［J］. Microb Pathog, 2017, 110: 630-636.
［21］Qin J, Li Y, Cai Z, et al. A metagenomewide association study of gut microbiota in type 2 diabetes［J］. Nature, 2012, 490(7418): 55-60.
［22］Sircana A, Framarin L, Leone N, et al. Altered gut microbiota in type 2 diabetes: just a coincidence?［J］. Curr Diab Rep, 2018, 18(10): 98.
［23］Odenwald MA, Turner JR. The intestinal epithelial barrier: a therapeutic target?［J］. Nat Rev Gastroenterol Hepatol, 2017, 14(1): 9-21.
［24］Groschwitz KR, Hogan SP. Intestinal barrier function: molecular regulation and disease pathogenesis［J］. J Allergy Clin Immunol, 2009, 124(1): 3-22.
［25］Mills S, Stanton C, Lane JA, et al. Precision nutrition and the microbiome, part I: current state of the science［J］. Nutrients, 2019, 11(4): 923.
［26］Plger S, Stumpff F, Penner GB, et al. Microbial butyrate and its role for barrier function in the gastrointestinal tract［J］. Ann N Y Acad Sci, 2012, 1258: 52-59.
［27］Feng Y, Wang Y, Wang P, et al. Shortchain fatty acids manifest stimulative and protective effects on intestinal barrier function through the inhibition of NLRP3 inflammasome and autophagy［J］. Cell Physiol Biochem, 2018, 49(1): 190-205.
［28］Allin KH, Nielsen T, Pedersen O. Mechanisms in endocrinology: Gut microbiota in patients with type 2 diabetes mellitus［J］. Eur J Endocrinol, 2015, 172(4): R167-R177.
［29］Chiang JYL, Pathak P, Liu H, et al. Intestinal farnesoid X receptor and takeda G protein couple receptor 5 signaling in metabolic regulation［J］. Dig Dis, 2017, 35(3): 241-245.
［30］Shen L, Ao L, Xu H, et al. Poor shortterm glycemic control in patients with type 2 diabetes impairs the intestinal mucosal barrier: a prospective, singlecenter, observational study［J］. BMC Endocr Disord, 2019, 19(1): 29.
［31］Johansson MEV, Sjvall H, Hansson GC. The gastrointestinal mucus system in health and disease［J］. Nat Rev Gastroenterol Hepatol, 2013, 10(6): 352-361.
［32］Schroeder BO. Fight them or feed them: how the intestinal mucus layer manages the gut microbiota［J］. Gastroenterol Rep (Oxf), 2019, 7(1): 3-12.
［33］Everard A, Belzer C, Geurts L, et al. Crosstalk between Akkermansia muciniphila and intestinal epithelium controls dietinduced obesity［J］. Proc Natl Acad Sci U S A, 2013, 110(22): 9066-9071.
［34］Riedel S, Pheiffer C, Johnson R, et al. Intestinal barrier function and immune homeostasis are missing links in obesity and type 2 diabetes development［J］. Front Endocrinol (Lausanne), 2021, 12: 833544.
［35］Depommier C, Everard A, Druart C, et al. Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proofofconcept exploratory study［J］. Nat Med, 2019, 25(7): 1096-1103.
［36］Parada Venegas D, De La Fuente MK, Landskron G, et al. Short chain fatty acids (SCFAs)mediated gut epithelial and immune regulation and its relevance for inflammatory bowel diseases［J］. Front Immunol, 2019, 10: 277.
［37］Scaldaferri F, Pizzoferrato M, Gerardi V, et al. The gut barrier: new acquisitions and therapeutic approaches［J］. J Clin Gastroenterol, 2012, 46（Suppl）: S12-S17.
［38］Martin AM, Sun EW, Rogers GB, et al. The influence of the gut microbiome on host metabolism through the regulation of gut hormone release［J］. Front Physiol, 2019, 10: 428.
［39］Bezirtzoglou E, Stavropoulou E, Kantartzi K, et al. Maintaining digestive health in diabetes: the role of the gut microbiome and the challenge of functional foods［J］. Microorganisms, 2021, 9(3): 516.
［40］Fasano A. Intestinal permeability and its regulation by zonulin: diagnostic and therapeutic implications［J］. Clin Gastroenterol Hepatol, 2012, 10(10): 1096-1100.
［41］Wassenaar TM, Zimmermann K. Lipopolysaccharides in food, food supplements, and probiotics: should we be worried?［J］. Eur J Microbiol Immunol (Bp), 2018, 8(3): 63-69.
［42］Hoffmanov I, Snchez D, Hbov V, et al. Serological markers of enterocyte damage and apoptosis in patients with celiac disease, autoimmune diabetes mellitus and diabetes mellitus type 2［J］. Physiol Res, 2015, 64(4): 537-546.